Wai Chun Bio-Technology Limited (stock code: 00660), referred to as WAI CHUN BIOTEC, released its Monthly Return report for February 2026. Total authorized share capital remained HKD 102.04 million, comprising 10.00 billion ordinary shares with a par value of HKD 0.01 and 204.00 million preference shares with a par value of HKD 0.01.

The company reported 178.48 million issued ordinary shares at the end of February, unchanged from the preceding month. Public float requirements continued to be met. The share option scheme reported 15.95 million outstanding share options, with no new shares issued during the month.

Four outstanding sets of convertible bonds totaled HKD 67.00 million, HKD 20.15 million, HKD 12.25 million, and HKD 15.00 million, respectively, with no new share conversions in February. The convertibles can potentially convert into a combined total of 1.97 billion ordinary shares. No treasury shares were reported, and no additional movements in issued shares were recorded.